118 related articles for article (PubMed ID: 24123104)
1. Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.
Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
Biopharm Drug Dispos; 2013 Dec; 34(9):527-39. PubMed ID: 24123104
[TBL] [Abstract][Full Text] [Related]
2. Population-based meta-analysis of furosemide pharmacokinetics.
Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
Biopharm Drug Dispos; 2014 Mar; 35(2):119-33. PubMed ID: 24151207
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.
Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
Biopharm Drug Dispos; 2013 Sep; 34(6):336-47. PubMed ID: 23794414
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation.
Commander SJ; Wu H; Boakye-Agyeman F; Melloni C; Hornik CD; Zimmerman K; Al-Uzri A; Mendley SR; Harper B; Cohen-Wolkowiez M; Hornik CP;
J Clin Pharmacol; 2021 Mar; 61(3):368-377. PubMed ID: 33029806
[TBL] [Abstract][Full Text] [Related]
6. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
7. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.
O'Grady P; Yee KF; Lins R; Mangold B
Br J Clin Pharmacol; 1999 Sep; 48(3):375-81. PubMed ID: 10510149
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
Möhrke W; Knauf H; Mutschler E
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
[TBL] [Abstract][Full Text] [Related]
12. Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats.
Wienen W; Schierok HJ
J Renin Angiotensin Aldosterone Syst; 2001 Jun; 2(2):123-8. PubMed ID: 11881111
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of cicletanine in healthy volunteers.
Pruñonosa J; Peraire C; Torrent J; Obach R
Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):265-70. PubMed ID: 1526688
[TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
Jönsson S; Simonsson US; Miller R; Karlsson MO
J Clin Pharmacol; 2015 Nov; 55(11):1268-79. PubMed ID: 25966665
[TBL] [Abstract][Full Text] [Related]
17. The potential for interaction of hydrochlorothiazide with garlic in rats.
Asdaq SM; Inamdar MN
Chem Biol Interact; 2009 Oct; 181(3):472-9. PubMed ID: 19660444
[TBL] [Abstract][Full Text] [Related]
18. Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study.
Agrawal SS; Aggarwal A
Contemp Clin Trials; 2010 Jul; 31(4):272-8. PubMed ID: 20382272
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension.
Bhad P; Ayalasomayajula S; Karan R; Leon S; Riviere GJ; Sunkara G; Jarugula V
J Clin Pharmacol; 2011 Jun; 51(6):933-42. PubMed ID: 20852001
[TBL] [Abstract][Full Text] [Related]
20. Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function.
Hersh AD; Kelly JG; Laher MS; Carmody M; Doyle GD
J Cardiovasc Pharmacol; 1996 Jan; 27(1):7-11. PubMed ID: 8656661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
